Physician profile
Chad E Travers
NPI 1932366697
$1,815.28
in general payments reported to CMS, 2019-2025
25 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $104 · 2021: $86.82 · 2022: $286 · 2023: $293 · 2024: $344 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $427.76 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $226.17 | 2019-2022 | |
| Amgen INC. | $203.08 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $161.29 | 2023-2025 | Wainua, Farxiga, Brilinta |
| Pfizer INC. | $129.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.35 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.24 | 2020-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $72.91 | 2019-2024 | |
| Lexicon Pharmaceuticals, INC. | $41.41 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $39.18 | 2025 | Onpattro, Amvuttra |
| Scpharmaceuticals INC. | $35.70 | 2025 | |
| Boston Scientific Corporation | $26.91 | 2024 | Watchman Flx |
| Altathera Pharmaceuticals LLC | $24.80 | 2022 | |
| Merck Sharp & Dohme LLC | $24.10 | 2022 | |
| Medtronic, INC. | $23.80 | 2025 | Corevalve Evolut R |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.34 | 2019-2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $21.73 | 2022 | |
| Mannkind Corporation | $18.41 | 2025 | |
| Bridgebio Pharma, INC. | $18.37 | 2025 | Attruby |
| Irhythm Technologies, INC. | $15.05 | 2019 | |
| Amarin Pharma, INC. | $13.98 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.38 | 2024 | Xarelto |
| Dexcom, INC. | $13.14 | 2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $12.97 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Travers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.